A
46.10
-0.31 (-0.67%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Akero Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.8
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.75 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.37% |
| 机构持股比例 | 109.31% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| General Atlantic, L.P. | 30 Jun 2025 | 5,733,989 |
| Avoro Capital Advisors Llc | 30 Jun 2025 | 3,500,000 |
| Deep Track Capital, Lp | 30 Jun 2025 | 3,042,598 |
| Bellevue Group Ag | 30 Jun 2025 | 1,985,272 |
| Alkeon Capital Management Llc | 30 Jun 2025 | 1,850,934 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 76.00 (TD Cowen, 64.86%) | 购买 |
| 中 | 74.00 (60.52%) | |
| 低 | 72.00 (HC Wainwright & Co., 56.18%) | 购买 |
| 平均值 | 74.00 (60.52%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 46.33 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Sep 2025 | 72.00 (56.18%) | 购买 | 44.03 |
| TD Cowen | 04 Aug 2025 | 76.00 (64.86%) | 购买 | 48.62 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合